

**VIVALIS PUBLISHES ITS  
REGISTRATION DOCUMENT**

**Nantes & Lyon (France) – April 27, 2012** – VIVALIS announces that its 2011 Registration Document has been filed with the Autorité des Marchés Financiers (« AMF ») on April 25, 2012 and registered under the number D.12-0412.

The registration document is available free of charge at VIVALIS' head office, 6, rue Alain Bombard, 44821 Saint-Herblain cedex, FRANCE and in electronic form on the company's web site ([www.vivalis.com](http://www.vivalis.com)) and on the web site of the AMF ([www.amf-france.org](http://www.amf-france.org)).

The following documents are incorporated into the 2010 Registration Document:

- The annual Financial Report,
- The report by the chairman of the Supervisory Board on the preparation and organisation conditions of the Supervisory Board and the internal control procedures implemented by the Company,
- The information relating to the fees paid by Statutory Auditors
- The annual information report.

\*\*\*\*\*

**Next financial press release:**

**July 19 2012, after NYSE Euronext market closing: 2012 first-semester sales**

**About VIVALIS ([www.vivalis.com](http://www.vivalis.com))**

VIVALIS (NYSE Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of unmet medical needs. VIVALIS' expertise and intellectual property are leveraged in three main areas:

**EB66<sup>®</sup> Cell Line**

VIVALIS offers research and commercial licenses for its EB66<sup>®</sup> cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLP's, and recombinant proteins (with a focus on monoclonal antibodies having enhanced cytotoxic activity). EB66<sup>®</sup> cell line based vaccines are currently in clinical trials in the USA and Japan. Through these programs VIVALIS receives upfront, clinical stage milestone payments along with royalties on licensees net sales.

**VIVA|Screen<sup>™</sup> Human Antibody Discovery Platform**

Customized solutions for the discovery, development, and production of fully human monoclonal antibodies are now offered by VIVALIS. Through these programs VIVALIS receives upfront, clinical stage milestone payments along with royalties on licensees net sales.

**3D-Screen<sup>™</sup> Drug Discovery Platform**

VIVALIS performs discovery and development, up to pre-clinical evaluation, of original small chemical molecules identified with its proprietary platform, 3D-Screen<sup>™</sup>. This unique screening platform is designed to identify original

molecules that alter the three-dimensional structure of a target protein, thus modulating its biological function through an innovative mode of action. VIVALIS is building a portfolio of proprietary new chemical entities for the treatment of hepatitis-C virus infection. VIVALIS also offers on a service basis to develop ready-to-use customized 3D-Screen™ HTS assays directed against target proteins of interest.

Based in Nantes & Lyon (France) and in Toyama (Japan) VIVALIS was founded in 1999 by the Grimaud Group (ca. 1,500 employees), a worldwide leader in animal genetic selection. VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Transgene, Pfizer Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Merck Animal Health, and SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bioclusters and a member of the Japanese HOKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE in Toyama.

#### VIVALIS

Listed on Euronext Paris – Compartment B of NYSE Euronext

Reuters: VLS.PA – Bloomberg: VLS FP

Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech indexes



*This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including the risk factors described in the company's registration document (document de référence), changes in economic conditions, the financial markets or the markets in which the company operates.*

#### **Contacts**

##### **VIVALIS**

Franck Grimaud, CEO

Email: [investors@vivalis.com](mailto:investors@vivalis.com)

##### **NewCap**

Communication financière

Axelle Vuillermet / Pierre Laurent

Tél.: +33 (0) 1 44 71 94 91

Email : [vivalis@newcap.fr](mailto:vivalis@newcap.fr)